Lack of association between methylenetetrahydrofolate reductase gene A1298C polymorphism and breast cancer susceptibility
Li-Xin Qiu,Jian Zhang,Wen-Hua Li,Qun-Ling Zhang,Hui Yu,Bi-Yun Wang,Lei-Ping Wang,Jia-Lei Wang,Hui-Jie Wang,Xiao-Jian Liu,Zhi-Guo Luo,Xiang-Hua Wu
DOI: https://doi.org/10.1007/s11033-010-0361-2
IF: 2.7422
2010-01-01
Molecular Biology Reports
Abstract:Published data on the association between methylenetetrahydrofolate reductase gene (MTHFR) A1298C polymorphism and breast cancer risk are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Medline, PubMed, Embase, and Web of Science were searched. Crude ORs with 95% CIs were used to assess the strength of association between the MTHFR A1298C polymorphism and breast cancer risk. The pooled ORs were performed for co-dominant model (AC vs. AA, CC vs. AA), dominant model (CC + AC vs. AA), and recessive model (CC vs. AC + AA), respectively. A total of 26 studies including 12,244 cases and 15,873 controls were involved in this meta-analysis. Overall, no significant associations were found between MTHFR A1298C polymorphism and breast cancer risk when all studies pooled into the meta-analysis (AC vs. AA: OR = 0.99, 95% CI 0.94–1.05; CC vs. AA: OR 0.99, 95% CI 0.90–1.09; dominant model: OR = 0.99, 95% CI 0.95–1.04; and recessive model: OR = 0.98, 95% CI 0.90–1.08). In the subgroup analysis by ethnicity or study design, still no significant associations were found for all comparison models. In conclusion, this meta-analysis suggests that the MTHFR A1298C polymorphism may be not associated with breast cancer development. However, large sample and representative population-based studies with homogeneous breast cancer patients and well matched controls are warranted to confirm this finding.